Canada has world-class biotech science. Too often, the companies built on it grow up somewhere else. Clarissa Desjardins, co-founder and CEO of Montreal’s Congruence Therapeutics, joins John Stackhouse on the state of biotech and what Canada must do to keep more of what it builds.
In this episode:
• How AI is changing the way new drugs are discovered
• Why China’s rise is reshaping the global industry
• Why biotech stays invisible in Canada, even to investors
• What it would take to grow Canadian companies to global scale at home
Chapters:
0:00 Will Canada's medicines come from China?
0:28 Biotech's missing place in Canada's agenda
1:32 From scientist to entrepreneur
3:47 Great science, too little commercialization
6:03 How AI is changing drug discovery
9:54 Why biotech is invisible, and underfunded
13:15 Health sovereignty and the anchor-company gap
18:33 China's rise in drug discovery
21:31 What Canada needs to do next
24:17 Closing thoughts
CONNECT & SUBSCRIBE:
• Follow RBC Thought Leadership onLinkedIn
• Follow John Stackhouse onLinkedIn
• For more insights visit RBC Thought Leadership
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
